Allogene Therapeutics (ALLO) Company Statistics | The Fly

Search...

/

Dashboard

Charting

KPIs

Stock Screener

ETF Screener

Earnings Calendar

Events Calendar

Syndicate

Street Research

Portfolios

Alert Settings

© 2026 The Fly Inc.

The Fly Cast

Press play to listen

©

Allogene Therapeutics (ALLO) Company Statistics | The Fly

Allogene Therapeutics

· ALLO

Dashboard

Financials

Ratios

Transcripts

Valuation

Statistics

559.695 M

-1.23%

General

Market Cap: $559.7M
Enterprise Value: $583.98M
Shares Outstanding: 345,150,000
Dividend: —
Employees: —
Revenue Per Employee: —

Fundamental Ratios (TTM)

Gross Margin: -699.35%
Operating Margin: -3886.14%
Net Profit Margin: -3566.68%
FCF Margin: -2211.16%
ROA: -30.08%
ROE: -50.04%
ROIC: -34.79%
Current Ratio: 10.72
Debt-to-Equity: 0.16
Revenue Per Employee: —

Valuation (TTM)

P/E: —
PEG: —
P/S: 119.02
P/FCF: —
P/B: 1.27
EV/EBITDA: -3.83

Growth

Rev 1Y: —
Rev 1Y Fwd Est: —
Rev 3Y (CAGR): —
Rev 5Y (CAGR): —
Rev 10Y (CAGR): —
EPS 1Y: —
EPS 1Y Fwd Est: —
EPS 3Y (CAGR): —
EPS 5Y (CAGR): —

Income Statement (TTM)

Revenue: $4.64M
Gross Margin: -699.35%
Operating Expenses: $147.87M
Operating Income: -$180.32M
Net Profit: -$165.49M

Balance Sheet

EPS 10Y (CAGR)

—

Cash and Equivalents: $38.63M
Working Capital: $308.27M
Total Assets: $550.09M
Net Debt: $31.73M
Total Liabilities: $113.92M
Total Equity: $436.18M

Cash Flow Statement (TTM)

Cash Flow from Operations: -$102.2M
Cash Flow from Investing: -$131.6M
Cash Flow from Financing: $220.09M
Free Cash Flow: -$102.6M
Capital Expenditures: $402K